EC Number |
Application |
Reference |
---|
3.3.2.6 | diagnostics |
LTA4H genes are risk factors for asthma in two different ethnic groups, individuals from Mexico and Puerto Rico |
708184 |
3.3.2.6 | diagnostics |
LTB4 can serve as a biomarker for evaluating bestatin efficacy in colorectal cancer and the antitumor effects of bestatin through its targeting of LTA4H |
753405 |
3.3.2.6 | drug development |
development of LTA4H inhibitors in cancer prevention and therapy |
752495 |
3.3.2.6 | drug development |
Drug repurposing of histone deacetylase inhibitors that alleviate neutrophilic inflammation in acute lung injury and idiopathic pulmonary fibrosis via inhibiting leukotriene A4 hydrolase and blocking LTB4 biosynthesis |
754386 |
3.3.2.6 | drug development |
drug repurposing of histone deacetylase inhibitors that alleviate neutrophilic inflammation in acute lung injury and idiopathic pulmonary fibrosis via inhibiting leukotriene A4 hydrolase and blocking LTB4 biosynthesis. Inhibiting LTB4 biosynthesis and subsequently neutrophilic inflammation may provide a potential strategy for the treatment of acute lung injury (ALI) and idiopathic pulmonary fibrosis (IPF) |
754386 |
3.3.2.6 | drug development |
possible therapeutic potential of targeting LTB4/BLT signaling in asthma, but production of LTB4 may not be responsible for airway neutrophils in severe asthma |
752450 |
3.3.2.6 | drug development |
the bifunctional enzyme is a target for development of selective inhibitors |
752956 |
3.3.2.6 | medicine |
enzyme overexpression appears to be an early event in esophageal adenocarcinogenesis and is a potential target for the chemoprevention of esophageal adenocarcinogenesis |
647020 |
3.3.2.6 | medicine |
findings suggest that agents affecting LTB4 biosynthetic pathway may prove useful for primary or secondary prevention of heart attacks |
683909 |
3.3.2.6 | medicine |
inhibition of LTB4 synthesis may be beneficial in the treatment of severe asthma and viral exacerbations of asthma, in which neutrophilic inflammation is more prominent |
708250 |